{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33531686",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "22"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "02",
    "Day": "04"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "02",
        "Day": "03"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1038/s41416-020-01246-0"
    ],
    "Journal": {
      "ISSN": "1532-1827",
      "JournalIssue": {
        "Volume": "124",
        "Issue": "8",
        "PubDate": {
          "Year": "2021",
          "Month": "Apr"
        }
      },
      "Title": "British journal of cancer",
      "ISOAbbreviation": "Br J Cancer"
    },
    "ArticleTitle": "More light on cancer and COVID-19 reciprocal interaction.",
    "Pagination": {
      "StartPage": "1344",
      "EndPage": "1345",
      "MedlinePgn": "1344-1345"
    },
    "Abstract": {
      "AbstractText": [
        "Cancer patients are vulnerable to COVID-19 with consequences on treatment delays and on mortality rate. This Comment explores the interaction between COVID-19 and cancer\u00a0with attention paid to the modulation by cancer treatments of both ADAM17 and TMPRSS2, the proteases which control ACE2 processing, the SARS-CoV-2 target."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0002-1252-4747"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 C\u00f4te d'Azur, IRCAN, Centre Antoine Lacassagne, CNRS, Inserm, FHU OncoAge, 06107, Nice, France."
          }
        ],
        "LastName": "Brest",
        "ForeName": "Patrick",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 C\u00f4te d'Azur, IRCAN, Centre Antoine Lacassagne, CNRS, Inserm, FHU OncoAge, 06107, Nice, France."
          }
        ],
        "LastName": "Mograbi",
        "ForeName": "Baharia",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 C\u00f4te d'Azur, IRCAN, Centre Antoine Lacassagne, CNRS, Inserm, FHU OncoAge, 06107, Nice, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 C\u00f4te d'Azur, CHU-Nice, Laboratory of Clinical and Experimental Pathology, FHU OncoAge, Hospital-Integrated Biobank (BB-0033-00025), 06001, Nice, France."
          }
        ],
        "LastName": "Hofman",
        "ForeName": "Paul",
        "Initials": "P"
      },
      {
        "Identifier": [
          "0000-0003-2478-0040"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 C\u00f4te d'Azur, Centre Antoine Lacassagne, UPR7497, 06100, Nice, France. gerard.milano@nice.unicancer.fr."
          }
        ],
        "LastName": "Milano",
        "ForeName": "Gerard",
        "Initials": "G"
      }
    ],
    "GrantList": [
      {
        "GrantID": "ANR-15-IDEX-01",
        "Agency": "Agence Nationale de la Recherche (French National Research Agency)",
        "Country": ""
      },
      {
        "GrantID": "ANR-11-LABX-0028-01",
        "Agency": "Agence Nationale de la Recherche (French National Research Agency)",
        "Country": ""
      },
      {
        "GrantID": "R19162DD",
        "Agency": "Agence Nationale de la Recherche (French National Research Agency)",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Br J Cancer",
    "NlmUniqueID": "0370635",
    "ISSNLinking": "0007-0920"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    },
    {
      "RegistryNumber": "EC 3.4.21.-",
      "NameOfSubstance": "Serine Endopeptidases"
    },
    {
      "RegistryNumber": "EC 3.4.21.-",
      "NameOfSubstance": "TMPRSS2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.24.86",
      "NameOfSubstance": "ADAM17 Protein"
    },
    {
      "RegistryNumber": "EC 3.4.24.86",
      "NameOfSubstance": "ADAM17 protein, human"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "ADAM17 Protein"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [
        "complications",
        "epidemiology",
        "genetics",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mortality"
    },
    {
      "QualifierName": [
        "complications",
        "epidemiology",
        "genetics",
        "virology"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [
        "genetics",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [
        "genetics"
      ],
      "DescriptorName": "Serine Endopeptidases"
    }
  ],
  "CoiStatement": "P.B., B.M. and P.H. declare no financial relationships with any organisations that might have an interest in the submitted work in the previous 3 years and no other relationships or activities that could appear to have influenced the submitted work. G.M. declares honorarium from BMS and Merck."
}